Table 6.
Sites selected by the MCFS as significant for resistance to Stavudine (NRTI). Only the top-scoring property is presented per site. Prevalence of mutations in the data and MCFS score are reported.
| Rank | Site | Property | Score | Prevalence | Status | |
|---|---|---|---|---|---|---|
| 1 | P215 | E oct-wat. | 101.72 | 0.54 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
| 3 | P210 | isoel. point | 82.64 | 0.26 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
| 11 | P67 | vdW vol. | 59.61 | 0.11 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
| 14 | P41 | isoel. point | 50.64 | 0.4 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
| 27 | P151 | vdW vol. | 26.31 | A0.04 | Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, zidovudine) | * |
| 29 | P75 | polarity | 22.94 | 0.09 | Known for NRTIs (stavudine) | * |
| 30 | P208 | isoel. point | 22.44 | 0.1 | Unknown | +++ |
| 31 | P118 | freq. helix | 22.24 | 0.17 | Known but considered unimportant | * |
| 33 | P44 | E oct-wat. | 21.59 | 0.1 | Known for NRTIs (tenofovir) | + |
| 35 | P69 | E oct-wat. | 21.02 | 0.15 | Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, tenofovir, zidovudine) | * |
| 47 | P219 | freq. turn | 18.15 | 0.27 | Known for NRTIs (didanosine, stavudine, zidovudine) | * |
| 48 | P70 | vdW vol. | 17.83 | 0.28 | Known for NRTIs (didanosine, stavudine, tenofovir, zidovudine) | * |
| 52 | P116 | polarity | 16.93 | 0.03 | Unknown | +++ |
| 60 | P43 | freq. helix | 15.78 | 0.14 | Unknown | +++ |
| 94 | P218 | freq. helix | 8.31 | 0.08 | Unknown | +++ |
| 96 | P228 | isoel. point | 7.83 | 0.14 | Unknown | +++ |
| 100 | P203 | freq. turn | 7.45 | 0.12 | Unknown | +++ |
| 101 | P122 | vdW vol. | 7.17 | 0.48 | Unknown | +++ |
| 103 | P184 | E sol. wat. | 6.63 | 0.56 | Known for NRTIs (abacavir, didanosine, lamivudine) | + |
| 110 | P211 | polarity | 5.9 | 0.54 | Unknown | +++ |
| 111 | P62 | E sol. wat. | 5.85 | 0.05 | Part of the multi-nRTi resistance complex. Affects all NRTIs except Tenofovir | * |
Symbols represent the status of a site:
*
Sites known to contribute to resistance to Stavudine;
+
Sites where mutations are associated with resistance to some NRTI drugs but not to Stavudine;
++
Sites where mutations contribute to resistance to NNRTI drugs;